Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa

Chen, Peifen1,2; Liu, Ziqiang3; Tan, Xin3; Wang, Haijiang1,2; Liang, Yiyang1,2; Kong, Yingjun1,2; Sun, Wenxue1,2; Sun, Liqin1,2; Ma, Yingfei3; Lu, Hongzhou1,2

2022-04-01

10.5582/bst.2022.01147

BioScience Trends   影响因子和分区

1881-7815

1881-7823

Pseudomonas aeruginosa is a frequent causative agent of post-pneumonectomy empyema-associated broncho-pleural fistula (BPF) and it has a high mortality rate. In recent years, the therapeutic potential of bacteriophage therapy has recognized anew as antimicrobial resistance increases globally. Studies are increasingly reporting the efficacy and safety of bacteriophage therapy for the treatment of multidrug-resistant bacterial infections. However, the clinical efficacy of bacteriophage therapy in empyema has seldom been studied. The current study reports the authors' experience with bacteriophage therapy for a 68-year-old Chinese man who suffered BPF-associated empyema and pneumonia caused by carbapenem-resistant P. aeruginosa. A personalized lytic pathogen-specific two-phage preparation was administered to the patient continuously for 24 days in combination with conventional antibiotics. The treatment was well-tolerated, resulting in clearance of the pathogen and improvement of the clinical outcome. This experience shows that a combined conventional antibiotic treatment with bacteriophage therapy may be effective at alleviating a multidrug-resistant bacterial infection in BPF-associated empyema.

bacteriophage therapy empyema carbapenem-resistant Pseudomonas aeruginosa pneumonia broncho-pleural fistula

SCI

英语

第一 ; 通讯

National Natural Science Foundation of China[32001038] ; Strategic Priority Research Program of the Chinese Academy of Sciences[XDB29050501] ; Guangdong Provincial Key Laboratory of Synthetic Genomics[2019B030301006] ; Shenzhen Key Laboratory of Synthetic Genomics[ZDSYS201802061806209] ; Shenzhen Institute of Synthetic Biology Scientific Research Program[JCHZ20200001] ; Shenzhen Third People's Hospital[G2022052]

Life Sciences & Biomedicine - Other Topics

Biology

WOS:000791411300001

IRCA-BSSA

Web of Science

1.Southern Univ Sci & Technol, Peoples Hosp Shenzhen 3, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China
2.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen 518112, Peoples R China
3.Chinese Acad Sci, CAS Key Lab Quantitat Engn Biol, Shenzhen Inst Adv Technol,Guangdong Prov Key Lab, Shenzhen Inst Synthet Biol,Shenzhen Key Lab Synth, Shenzhen, Peoples R China

Chen, Peifen,Liu, Ziqiang,Tan, Xin,et al. Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa[J]. BioScience Trends,2022.

Chen, Peifen.,Liu, Ziqiang.,Tan, Xin.,Wang, Haijiang.,Liang, Yiyang.,...&Lu, Hongzhou.(2022).Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa.BioScience Trends.

Chen, Peifen,et al."Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa".BioScience Trends (2022).